Tissue specificity of in vitro drug sensitivity

Fupan Yao, Seyed Ali Madani Tonekaboni, Zhaleh Safikhani, Petr Smirnov, Nehmé El-Hachem, Mark Freeman, Venkata Manem, Benjamin Haibe‐KainsbioRxiv 2016 · DOI

Abstract

Research in oncology traditionally focuses on the specific tissue type from which a cancer develops. While molecular profiling has promised a shift toward classifying tumors by genetic aberrations, clinical evidence suggests that tumors with similar mutations respond differently depending on their tissue of origin. This study investigates the tissue specificity of drug sensitivities across four large-scale pharmacological datasets and compares these associations to clinical trial data. Our meta-analysis reveals that tissue of origin remains a dominant predictor of drug response in vitro, yet a significant "translational gap" exists, as most preclinical associations fail to align with clinical observations.

Introduction: The Persistence of Tissue Type in Precision Medicine

For decades, cancer treatment was defined by the primary site of the tumor. The advent of high-throughput sequencing sparked a paradigm shift toward "precision medicine," where tumors are classified by molecular mutations regardless of location. The hope was that a drug targeting a specific mutation would be effective across all tissues harboring that mutation. However, clinical reality is more complex; patients with identical genetic aberrations often exhibit disparate responses based on their tissue of origin. This study aims to quantify the influence of tissue type on drug sensitivity in laboratory settings and evaluate how well these findings translate to human clinical trials.

Methods: Standardizing Pharmacogenomic Data

The researchers performed a massive meta-analysis using the PharmacoGx platform to standardize disparate pharmacogenomic datasets. A critical step involved re-fitting thousands of drug dose-response curves to a unified mathematical model to ensure "apples-to-apples" comparisons of drug sensitivity, primarily measured by the Area Under the Curve (AUC).

The unified four-parameter logistic equation used to re-fit drug dose-response curves across datasets.

The study also introduced Tissue Enrichment Analysis (TEA). Inspired by Gene Set Enrichment Analysis (GSEA), TEA identifies whether cell lines sensitive to a specific drug are significantly enriched within a particular tissue type. The analysis leveraged four major datasets: CCLE, GDSC1000, CTRPv2, and gCSI, covering 727 drugs and 1,527 unique cancer cell lines across 35 tissue types. Clinical concordance was assessed by mining ClinicalTrials.gov and using the Matthew Correlation Coefficient (MCC) to quantify agreement between preclinical and clinical data.

Results: The Dominance of Tissue and the Translational Gap

Tissue-Specific Sensitivity is Pervasive

The meta-analysis revealed that 87% of the drugs tested (631 out of 722) showed significant tissue-specific sensitivity in vitro. This confirms that tissue of origin remains a powerful biomarker in laboratory models. Notably, drugs like 17-AAG, trametinib, and afatinib demonstrated enriched sensitivity across more than five different tissue types.

The "Private" Association and Hematopoietic Bias

Over half of the significant drug-tissue associations were "private," appearing in only one dataset. This underscores the necessity of meta-analyses to avoid false positives inherent in single-study designs. Furthermore, cell lines from hematopoietic and lymphoid tissues (blood cancers) were significantly more sensitive to over 65% of all drugs tested, suggesting a general "fragility" or higher responsiveness to chemical stress compared to solid tumor lines.

The Disconnect from Clinical Reality

The most striking finding was the lack of overlap between lab-discovered associations and clinical trial data (MCC = -0.004). While a few "gold standard" associations—such as afatinib and lapatinib in breast cancer—were conserved, the vast majority of preclinical signals did not translate to the clinic.

Discussion: Bridging the Gap

The authors identify several factors contributing to this translational failure, including model limitations where standard cell lines lack the complex tumor microenvironment, and genomic drift caused by prolonged in vitro culture. To bridge this gap, the study suggests moving toward more complex models, such as patient-derived organoids or xenografts, and calls for more rigorous investigation into the root causes of preclinical-to-clinical discrepancies.

Summary updated

Abstract

ABSTRACT Research in oncology traditionally focuses on specific tissue type from which the cancer develops. However, advances in high-throughput molecular profiling technologies have enabled the comprehensive characterization of molecular aberrations in multiple cancer types. It was hoped that these large-scale datasets would provide the foundation for a paradigm shift in oncology which would see tumors being classified by their molecular profiles rather than tissue types, but tumors with similar genomic aberrations may respond differently to targeted therapies depending on their tissue of origin. There is therefore a need to reassess the potential association between pharmacological response and tissue of origin for therapeutic drugs, and to test how these associations translate from preclinical to clinical settings. In this paper, we investigate the tissue specificity of drug sensitivities in large-scale pharmacological studies and compare these associations to those found in clinical trial descriptions. Our meta-analysis of the four largest in vitro drug screening datasets indicates that tissue of origin is strongly associated with drug response. We identify novel tissue-drug associations, which may present exciting new avenues for drug repurposing. One caveat is that the vast majority of the significant associations found in preclinical settings do not concur with clinical observations. Accordingly, our results call for more testing to find the root cause of the discrepancies between preclinical and clinical observations.
BibTeX
@misc{yao2016tissue,
  author = {Fupan Yao and Seyed Ali Madani Tonekaboni and Zhaleh Safikhani and Petr Smirnov and Nehmé El-Hachem and Mark Freeman and Venkata Manem and Benjamin Haibe‐Kains},
  title = {{Tissue specificity of <i>in vitro</i> drug sensitivity}},
  year = {2016},
  doi = {10.1101/085357},
  howpublished = {bioRxiv},
}
Figure